Company Profile · Healthcare

Insulet Corporation

PODD · US
Exchange
US
Country
USA
IPO date
May 15, 2007
Employees
5,400
Current Price
$145.76
Live · Jun 18, 2026
Fair Buy
≤ $120
Margin-of-safety entry
Baillie Growth Score
51/100
Medium
Intrinsic Value · Three-Tier Range Current price $145.76 Live · Within the fair intrinsic-value range

Composite valuation range · conservative $110–$120 / fair $120–$160 / optimistic $170–$190. At $145.76, Within the fair intrinsic-value range.

At publication $144.94 (May 31, 2026)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Market cap$9.94B
Revenue (TTM)$2.9B
EBITDA$602M
Profit margin10.44%
ROE23%
P/E (TTM)33.53
Forward P/E23.09
PEG1.27
EPS$4.28
52-week range$140.63 – $354.88
Analyst target$242.43
Analyst rating4.6 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.